Septerna(SEPN.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Septerna
SEPN.US
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.
4.853 T
SEPN.USMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking68/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-39.03%E
    • Profit Margin-266.77%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY2147.20%A
    • Net Profit YoY-196.28%E
    • Total Assets YoY248.09%A
    • Net Assets YoY184.27%A
  • Cash ScoreB
    • Cash Flow Margin-37.49%D
    • OCF YoY2147.20%A
  • Operating ScoreE
    • Turnover0.06E
  • Debt ScoreB
    • Gearing Ratio35.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HC Wainwright Issues Negative Forecast for Septerna Earnings

    HC Wainwright has revised its FY2025 earnings per share (EPS) estimate for Septerna, Inc. (NASDAQ:SEPN) from ($1.45) to ($1.53). The analyst maintains a "Buy" rating with a price target of $35.00. The consensus estimate for Septerna's full-year earnings is ($7.11) per share. The stock has seen various ratings, with one strong buy, five buys, and one sell. Septerna's stock opened at $26.35, down 2.5%, with a market cap of $1.18 billion. Recent quarterly earnings reported a loss of ($0.09) per share, missing estimates.

    Market Beat·
    US
    SEPN
    +1.21%
    Market Beat·
    US
    SEPN
    +1.21%

    Septerna Inc. Files Initial Beneficial Ownership Statement for Chief Legal Officer Mark Andrew Wilson

    Septerna Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, naming Mark Andrew Wilson as the beneficial owner and Chief Legal Officer. The filing is accessible through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    SEPN
    +1.21%
    Reuters·
    US
    SEPN
    +1.21%

    Septerna to Present GPCR Pipeline Updates at JPM Conference

    Septerna, Inc. (SEPN) will present updates on its GPCR pipeline at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company plans to initiate a Phase 1 trial for SEP-479, an oral PTH1R agonist, and present data for SEP-631, an oral MRGPRX2 modulator. Septerna has a collaboration with Novo Nordisk and expects to fund operations into 2029. Analysts rate SEPN stock as a Hold with a $27.00 price target, citing weak financial performance despite revenue growth. The current market cap is $1.15B.

    Tip Ranks·
    US
    SEPN
    +1.21%
    Tip Ranks·
    US
    SEPN
    +1.21%

    Septerna Inc. Names Mark A. Wilson as Chief Legal Officer

    Septerna Inc. has appointed Mark A. Wilson as Chief Legal Officer. Wilson has over 25 years of experience in the pharmaceutical and biotech sectors, previously serving as Senior Vice President and Chief Legal Officer at Nektar Therapeutics. This announcement was published via GlobeNewswire.

    Reuters·
    US
    SEPN
    +1.21%
    Reuters·
    US
    SEPN
    +1.21%

    Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading

    Jones Trading initiated coverage on Septerna (NASDAQ:SEPN) with a "buy" rating and a $43.00 target price, suggesting a 45.91% upside. Other analysts have varied ratings, with a consensus "Moderate Buy" and a $33.00 target. Septerna's stock opened at $29.47, with a market cap of $1.32 billion. The company focuses on GPCR therapies in endocrinology, immunology, and metabolic diseases.

    Market Beat·
    US
    SEPN
    +1.21%
    Market Beat·
    US
    SEPN
    +1.21%
    © 2026 Longbridge｜Disclaimer